




The relative strengths and weaknesses of Avanir Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Avanir Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 90% points. The greatest weakness of Avanir Pharmaceuticals INC is the variable Other Expenses, reducing the Economic Capital Ratio by 22% points.

The company's Economic Capital Ratio, given in the ranking table, is 382%, being 128% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	300,817
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	32,093
Liabilities, Non-Current	1,501
Other Assets	2,535
Other Compr. Net Income	0
Other Expenses	84,493
Other Liabilities	0
Other Net Income	-777
Other Revenues	115,029
Property and Equipment	3,631
Research and Development	44,004
Selling, General and Administrative Expense	36,191

Output Variable	Value in 1000 USD
Assets	306,983
Liabilities	33,594
Expenses	164,688
Revenues	115,029
Stockholders Equity	273,389
Net Income	-50,436
Comprehensive Net Income	-50,436
BaseVar	310,536
ECR before LimitedLiability	320%
Economic Capital Ratio	382%